camrelizumab + cetuximab + chemotherapy

Camrelizumab + cetuximab + chemotherapy is an investigational combination therapy regimen being evaluated for the treatment of metastatic colorectal cancer (mCRC). The regimen consists of camrelizumab, a humanized monoclonal antibody targeting the programmed cell death protein 1 (PD-1) receptor; cetuximab, a chimeric monoclonal antibody that inhibits the epidermal growth factor receptor (EGFR); and a chemotherapy backbone, typically the mFOLFOX6 regimen (oxaliplatin, leucovorin, and 5-fluorouracil). This triplet therapy is primarily being studied by Harbin Medical University Cancer Hospital as a first-line treatment for patients with RAS/BRAF wild-type mCRC. The therapeutic rationale involves leveraging the synergistic effects of immune checkpoint inhibition, targeted EGFR blockade, and cytotoxic chemotherapy to overcome resistance and improve clinical outcomes in this specific patient population.

Other names

Camrelizumab plus Cetuximab plus mFOLFOX6